GSKH - ETF AI Analysis

Compare

Top Page

GSK plc ADRhedged (GSKH)

Rating:75Outperform

Price Target:

$70.00

The ETF GSKH has a strong overall rating, largely driven by its significant exposure to GSK, which accounts for over 97% of the fund's holdings. GSK's strong earnings performance, favorable valuation metrics, and strategic focus on high-growth segments contribute positively to the ETF's rating. However, the fund's heavy concentration in a single holding may pose a risk if GSK's performance falters in the future.

Positive Factors

Strong Top Holding

The ETF’s largest position, GlaxoSmithKline, has delivered strong year-to-date performance, driving overall fund returns.

Low Expense Ratio

The ETF charges a very low expense ratio, making it cost-effective for investors compared to similar funds.

Consistent Short-Term Performance

The fund has shown steady gains over the past month and three months, reflecting solid momentum.

Negative Factors

Over-Concentration in One Stock

Nearly all of the ETF’s assets are invested in a single company, exposing investors to significant company-specific risk.

Sector Overexposure

The fund is heavily concentrated in the health care sector, limiting diversification and increasing vulnerability to sector-specific downturns.

Minimal Geographic Diversification

The ETF is almost entirely focused on U.S. companies, offering little exposure to international markets.

GSKH vs. SPDR S&P 500 ETF (SPY)

AUM622.70K

RegionEurope

Expense Ratio0.19%

Beta0.22

IssuerADRhedged

Inception DateJan 07, 2025

Dividend YieldN/A

Asset ClassEquity

Index TrackedGSK plc - Benchmark Price Return

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume964

30 Day Avg. Volume370

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

60.26

Price Target Upside― Downside

Rating ConsensusHold

Number of Analyst Covering2

GSKH Summary

The GSK plc ADRhedged ETF (Ticker: GSKH) focuses on the pharmaceutical sector within healthcare, offering exposure to companies like GlaxoSmithKline. This ETF is designed to benefit from the growth and innovation in drug development and healthcare advancements, while also protecting against currency fluctuations for American Depository Receipts (ADRs). It’s a great option for investors looking to diversify into healthcare and potentially benefit from breakthroughs in medicine and global health initiatives. However, since it’s heavily focused on pharmaceuticals, its performance can be impacted by industry-specific challenges like regulatory changes or slower-than-expected drug approvals.

How much will it cost me?The GSK plc ADRhedged ETF has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed ETFs, as it focuses on a specific niche in the pharmaceutical sector while offering currency hedging benefits.

What would affect this ETF?The GSKH ETF could benefit from positive trends in the pharmaceutical sector, such as advancements in drug development, regulatory approvals, and increased demand driven by aging populations and global health initiatives. However, it may face challenges from stricter regulations, patent expirations, or economic downturns that could impact healthcare spending. Additionally, its focus on the U.K. market and reliance on GlaxoSmithKline may expose it to risks tied to regional economic conditions or company-specific performance.

GSKH Top 10 Holdings

The GSK plc ADRhedged ETF (GSKH) is laser-focused on the pharmaceutical sector, with GlaxoSmithKline (GSK) dominating the portfolio at nearly full weight. GSK has been steady to rising recently, buoyed by strong earnings and a strategic emphasis on high-growth areas like innovative drug development. This concentrated exposure means the fund’s performance is almost entirely tied to GSK’s trajectory, offering little diversification but a clear bet on one of the U.K.’s healthcare giants. Investors seeking targeted exposure to European pharmaceuticals may find this fund compelling, though its reliance on a single name could amplify risks.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
GSK	GlaxoSmithKline	95.98%	$628.55K	$92.97B	24.10%	77 Outperform

GSKH Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

58.99

Positive

100DMA

56.33

Positive

200DMA

54.97

Positive

Market Momentum

MACD

1.34

Negative

RSI

66.77

Neutral

STOCH

51.96

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSKH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 62.18, equal to the 50-day MA of 58.99, and equal to the 200-day MA of 54.97, indicating a bullish trend. The MACD of 1.34 indicates Negative momentum. The RSI at 66.77 is Neutral, neither overbought nor oversold. The STOCH value of 51.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GSKH.

GSKH Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
GSKH	―	―	$622.70K	0.19%	75 Outperform
HSBH	―	―	$7.79M	0.19%	73 Outperform
SHEH	―	―	$3.85M	0.19%	71 Outperform
AZNH	―	―	$1.51M	0.19%	75 Outperform
BPH	―	―	$1.09M	0.19%	55 Neutral
ARMH	―	―	$773.18K	0.19%	75 Outperform

Performance Comparison

GSKH

GSK plc ADRhedged

65.70

15.45

30.75%

HSBH

HSBC Holdings plc ADRhedged

―

SHEH

Shell plc ADRhedged

―

AZNH

AstraZeneca PLC ADRhedged

―

BPH

BP p.l.c. ADRhedged

―

ARMH

Arm Holdings PLC ADRhedged

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents